Literature DB >> 20029950

Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.

Courtney D Fitzhugh1, Naudia Lauder, Jude C Jonassaint, Marilyn J Telen, Xiongce Zhao, Elizabeth C Wright, Francis R Gilliam, Laura M De Castro.   

Abstract

Sickle cell disease (SCD) is associated with early mortality. We sought to determine the incidence, cause, and risk factors for death in an adult population of patients with SCD. All patients aged >/=18 years seen at the Adult Sickle Cell Center at Duke University Medical Center between January 2000 and April 2005 were enrolled. Forty-three patients (21 males and 22 females) died during the study period. The median age of survival was 39 years for females (95% CI: 34-56), 40 years for males (95% CI: 34-48), and 40 years overall (95% CI: 35-48). Cardiac causes of death accounted for 25.6% (11/43 patients); pulmonary, 14.0% (six patients); other SCD related, 32.6% (14 patients); unknown, 14.0% (six patients); and others, 14.0% (six patients). Pulseless electrical activity arrest, pulmonary emboli, multiorgan failure, and stroke were the most frequent causes of death. Among the deceased patients, the most common premorbid conditions were cardiopulmonary: acute chest syndrome/pneumonia (58.1%), Pulmonary hypertension (pHTN; 41.9%), systemic HTN (25.6%), congestive heart failure (25.6%), myocardial infarction (20.9%), and arrhythmias (14.0%). Tricuspid regurgitant jet velocity was significantly higher (3.1 m/sec vs. 2.6 m/sec, P < 0.001) and hemoglobin significantly lower (8.3 g/dL vs. 9.2 g/dL, P < 0.05) in deceased patients when compared with patients who lived, respectively. With improved preventive and therapeutic advances, including hydroxyurea therapy, acute complications such as infection are no longer the leading cause of death; instead, causes of death and premorbid conditions are shifting to chronic cardiopulmonary complications. Further, arrhythmia leading to premature death is under-recognized in SCD and warrants further investigation. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20029950      PMCID: PMC3865703          DOI: 10.1002/ajh.21569

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  48 in total

Review 1.  The lung in sickle cell disease.

Authors:  J Knight; T M Murphy; I Browning
Journal:  Pediatr Pulmonol       Date:  1999-09

2.  Mortality in sickle cell patients on hydroxyurea therapy.

Authors:  Sule M Bakanay; Erin Dainer; Betsy Clair; Adekunle Adekile; Lisa Daitch; Leigh Wells; Leslie Holley; David Smith; Abdullah Kutlar
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

3.  National trends in the mortality of children with sickle cell disease, 1968 through 1992.

Authors:  H Davis; K C Schoendorf; P J Gergen; R M Moore
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

4.  Pulmonary hypertension in patients with sickle cell disease: a longitudinal study.

Authors:  Kenneth I Ataga; Charity G Moore; Susan Jones; Oludamilola Olajide; Dell Strayhorn; Alan Hinderliter; Eugene P Orringer
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

5.  Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease.

Authors:  Subha V Raman; Orlando P Simonetti; Spero R Cataland; Eric H Kraut
Journal:  Haematologica       Date:  2006-10       Impact factor: 9.941

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

8.  Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.

Authors:  Darleen R Powars; Linda S Chan; Alan Hiti; Emily Ramicone; Cage Johnson
Journal:  Medicine (Baltimore)       Date:  2005-11       Impact factor: 1.889

9.  Medical care utilization and mortality in sickle cell disease: a population-based study.

Authors:  Sadhna M Shankar; Patrick G Arbogast; Ed Mitchel; William O Cooper; Winfred C Wang; Marie R Griffin
Journal:  Am J Hematol       Date:  2005-12       Impact factor: 10.047

10.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

Authors:  Roberto F Machado; Anastasia Anthi; Martin H Steinberg; Duane Bonds; Vandana Sachdev; Gregory J Kato; Angelo M Taveira-DaSilva; Samir K Ballas; William Blackwelder; Xiuli Xu; Lori Hunter; Bruce Barton; Myron Waclawiw; Oswaldo Castro; Mark T Gladwin
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

View more
  69 in total

Review 1.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

2.  Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.

Authors:  Patrick T McGann; Omar Niss; Min Dong; Anu Marahatta; Thad A Howard; Tomoyuki Mizuno; Adam Lane; Theodosia A Kalfa; Punam Malik; Charles T Quinn; Russell E Ware; Alexander A Vinks
Journal:  Am J Hematol       Date:  2019-06-12       Impact factor: 10.047

3.  Subclinical left ventricular systolic impairment in steady state young adult patients with sickle-cell anemia.

Authors:  Nadjib Hammoudi; Dimitri Arangalage; Morad Djebbar; Katia Stankovic Stojanovic; Magali Charbonnier; Richard Isnard; Robert Girot; Pierre-Louis Michel; François Lionnet
Journal:  Int J Cardiovasc Imaging       Date:  2014-06-22       Impact factor: 2.357

4.  Abnormalities in aortic properties: a potential link between left ventricular diastolic function and ventricular-aortic coupling in sickle cell disease.

Authors:  Emilie Bollache; Nadjia Kachenoura; Roberto M Lang; Ankit A Desai; Victor Mor-Avi; Amit R Patel
Journal:  Int J Cardiovasc Imaging       Date:  2016-02-23       Impact factor: 2.357

Review 5.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 6.  Cardiovascular abnormalities in sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

7.  Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia.

Authors:  Omar Niss; Robert Fleck; Fowe Makue; Tarek Alsaied; Payal Desai; Jeffrey A Towbin; Punam Malik; Michael D Taylor; Charles T Quinn
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

Review 8.  The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.

Authors:  Michael R DeBaun; Robert C Strunk
Journal:  Lancet       Date:  2016-06-18       Impact factor: 79.321

9.  Effect of propranolol as antiadhesive therapy in sickle cell disease.

Authors:  Laura M De Castro; Rahima Zennadi; Jude C Jonassaint; Milena Batchvarova; Marilyn J Telen
Journal:  Clin Transl Sci       Date:  2012-10-17       Impact factor: 4.689

Review 10.  Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants.

Authors:  Shalini Shenoy
Journal:  Stem Cells Transl Med       Date:  2013-04-11       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.